GenEp, Inc. is a privately held pre-clinical stage biotechnology company based on the licensed intellectual property portfolio of University of Virginia researcher Manoj Patel.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/genep
Nanochon, Inc. is a privately held biotechnology company that is developing an implant that is designed to not only replace lost and damaged cartilage but also to encourage new tissue growth.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/nanochon
A privately held pre-clinical stage biotechnology company, spun out of the University of Virginia, creating therapies that restore the body's natural immunological response in various diseases.
lvg.virginia.edu/ventures/slate-bio
Merand Pharmaceuticals is developing a novel microRNA therapeutic (MicroRNA93 or miR-93), which was discovered at UVA, to treat patients suffering from Peripheral Arterial Disease.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/merand-pharmaceuticals
Direct Spinal Therapeutics, Inc. is a medical device company developing a Spinal Cord Stimulation (SCS) product-platform to enhance treatment for chronic back pain and other spinal cord injuries.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/direct-spinal-therapeutics
BrightSpec is a commercial-stage life science instrumentation company.
lvg.virginia.edu/ventures/brightspec
Ceres Nanosciences Inc. is engaged in the research, development, and commercialization of innovative sample preparation products and diagnostic tests, based on its proprietary Nanotrap® particle platform.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/ceres-nanosciences
MSi provides industrial control system cybersecurity visibility and protection to leading businesses in energy, smart cities, critical infrastructure and the military.
lvg.virginia.edu/ventures/mission-secure
TearSolutions has developed ‘Lacripep’, which is derived from Lacritin protein as a first-in-class topical therapy that preserves all of Lacritin’s bioactivity.
lvg.virginia.edu/ventures/tearsolutions
Astraea exists to demystify the complexity of our planet for those who seek to understand it.
lvg.virginia.edu/uva-lvg-seed-fund/portfolio/astraea
TypeZero is leveraging more than 10 years of clinical trials, research, and innovation to develop the inControl Diabetes Management Platform to improve and simplify the lives of people with diabetes.
lvg.virginia.edu/ventures/typezero-technologies
510 Kardiac Devices, Inc. is an early stage medical device company developing novel technologies for cardiovascular surgical procedures.
lvg.virginia.edu/ventures/510kardiac-devices-inc
